These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31283930)

  • 1. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.
    Lavall D; Jacobs N; Mahfoud F; Kolkhof P; Böhm M; Laufs U
    Biochem Pharmacol; 2019 Oct; 168():173-183. PubMed ID: 31283930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rac1 GTPase regulates 11β hydroxysteroid dehydrogenase type 2 and fibrotic remodeling.
    Lavall D; Schuster P; Jacobs N; Kazakov A; Böhm M; Laufs U
    J Biol Chem; 2017 May; 292(18):7542-7553. PubMed ID: 28320863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.
    Lavall D; Selzer C; Schuster P; Lenski M; Adam O; Schäfers HJ; Böhm M; Laufs U
    J Biol Chem; 2014 Mar; 289(10):6656-6668. PubMed ID: 24469458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice.
    Adam O; Zimmer C; Hanke N; Hartmann RW; Klemmer B; Böhm M; Laufs U
    J Mol Cell Cardiol; 2015 Aug; 85():140-50. PubMed ID: 26047574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation.
    Adam O; Theobald K; Lavall D; Grube M; Kroemer HK; Ameling S; Schäfers HJ; Böhm M; Laufs U
    J Mol Cell Cardiol; 2011 Apr; 50(4):678-85. PubMed ID: 21215756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation.
    Adam O; Lavall D; Theobald K; Hohl M; Grube M; Ameling S; Sussman MA; Rosenkranz S; Kroemer HK; Schäfers HJ; Böhm M; Laufs U
    J Am Coll Cardiol; 2010 Feb; 55(5):469-80. PubMed ID: 20117462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction.
    Gueret A; Harouki N; Favre J; Galmiche G; Nicol L; Henry JP; Besnier M; Thuillez C; Richard V; Kolkhof P; Mulder P; Jaisser F; Ouvrard-Pascaud A
    Hypertension; 2016 Apr; 67(4):717-23. PubMed ID: 26902493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway.
    Martínez-Martínez E; Buonafine M; Boukhalfa I; Ibarrola J; Fernández-Celis A; Kolkhof P; Rossignol P; Girerd N; Mulder P; López-Andrés N; Ouvrard-Pascaud A; Jaisser F
    Hypertension; 2017 Dec; 70(6):1148-1156. PubMed ID: 29061727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
    Lachaux M; Barrera-Chimal J; Nicol L; Rémy-Jouet I; Renet S; Dumesnil A; Wecker D; Richard V; Kolkhof P; Jaisser F; Ouvrard-Pascaud A; Mulder P
    Diabetes Obes Metab; 2018 Oct; 20(10):2399-2407. PubMed ID: 29862614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
    Ayuzawa N; Nagase M; Ueda K; Nishimoto M; Kawarazaki W; Marumo T; Aiba A; Sakurai T; Shindo T; Fujita T
    Hypertension; 2016 Jan; 67(1):99-106. PubMed ID: 26527051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
    Grune J; Beyhoff N; Smeir E; Chudek R; Blumrich A; Ban Z; Brix S; Betz IR; Schupp M; Foryst-Ludwig A; Klopfleisch R; Stawowy P; Houtman R; Kolkhof P; Kintscher U
    Hypertension; 2018 Apr; 71(4):599-608. PubMed ID: 29437893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
    Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling.
    Reil JC; Hohl M; Oberhofer M; Kazakov A; Kaestner L; Mueller P; Adam O; Maack C; Lipp P; Mewis C; Allessie M; Laufs U; Böhm M; Neuberger HR
    Cardiovasc Res; 2010 Aug; 87(3):485-93. PubMed ID: 20211865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.